How Does Metronidazole Work Complete Guide 2026
How Does Metronidazole Work?
The Antibiotic That Activates Like a Trojan Horse
Imagine a medication that remains completely inactive until it enters the very cells it’s designed to kill. Only then, in the dark, oxygen-free environment of certain bacteria, does it transform into a lethal weapon that shreds DNA and destroys the organism from within. This isn’t science fiction—this is precisely how metronidazole works, and this unique mechanism explains why, after nearly 70 years, no other antibiotic has replaced it for treating some of the most dangerous infections known to medicine.
Consider this: before metronidazole’s discovery, a ruptured appendix with anaerobic sepsis carried a mortality rate exceeding 60%. Brain abscesses caused by Bacteroides species were frequently fatal. Today, a patient with these same conditions receives intravenous metronidazole and typically walks out of the hospital within two weeks. That transformation represents one of the most dramatic revolutions in infectious disease management—and it all stems from understanding how does metronidazole work at the molecular level.
Key Facts About Metronidazole
| Parameter | Essential Information |
|---|---|
| Drug Name | Metronidazole (Flagyl) |
| Drug Class | Nitroimidazole antimicrobial |
| How It Works | Prodrug activated by anaerobic reduction; damages DNA |
| First Synthesized | 1955 (Rhône-Poulenc, France) |
| FDA Approval | 1963 |
| WHO Essential Medicine | Yes, since 1977 |
| Oral Bioavailability | Greater than 90% |
| Half-Life | 6-8 hours (normal hepatic function) |
| Primary Elimination | Hepatic metabolism (CYP3A4) |
| Pregnancy Category | Compatible when indicated (all trimesters per current evidence) |
| Alcohol Interaction | Disulfiram-like reaction (contraindicated) |
| Routes Available | Oral, IV, topical, vaginal, dental gel |
Understanding How Metronidazole Works
How does metronidazole work in the body? This question lies at the heart of clinical infectious disease practice. Metronidazole operates through a mechanism unlike any other commonly prescribed antibiotic. While penicillins attack cell walls and macrolides block protein synthesis, metronidazole remains completely inactive in its administered form. It requires activation by bacterial enzymes found only in anaerobic (oxygen-free) environments, making it selectively lethal to organisms that thrive where oxygen cannot reach.
This selectivity explains everything about metronidazole’s clinical use. It explains why the drug treats brain abscesses, intra-abdominal infections, and dental abscesses—all sites where anaerobic bacteria flourish. It explains why metronidazole does nothing against aerobic bacteria like Streptococcus or Escherichia coli. And it explains why human cells, with their oxygen-rich metabolism, generally tolerate the drug without experiencing the DNA damage that kills susceptible bacteria.
The clinical importance of understanding how does metronidazole work extends beyond academic curiosity. Prescribing errors frequently occur when clinicians forget that metronidazole covers anaerobes but not aerobes, leading to inadequate empiric therapy for mixed infections. Understanding the mechanism prevents these potentially fatal mistakes.
Historical Background: The Accidental Discovery
The story of how does metronidazole work begins not with deliberate antibiotic development but with a search for antiprotozoal compounds. In 1955, chemists at Rhône-Poulenc Laboratories in France synthesized a series of nitroimidazole derivatives while screening for activity against Trichomonas vaginalis. Compound 8823 RP—later named metronidazole—demonstrated potent trichomonacidal activity and entered clinical testing.
The pivotal observation occurred in 1962 when D.L. Shinn, a British dentist, reported that a patient treated with metronidazole for trichomonal vaginitis experienced simultaneous resolution of acute necrotizing ulcerative gingivitis. This chance finding revealed metronidazole’s activity against anaerobic bacteria, opening an entirely new therapeutic domain.
Before this discovery, anaerobic infections posed formidable challenges. Bacteroides fragilis, the most common anaerobic pathogen in intra-abdominal sepsis, resisted most available antibiotics. Surgeons faced mortality rates exceeding 60% for generalized peritonitis involving anaerobes. Metronidazole changed this landscape dramatically, and understanding how does metronidazole work became essential knowledge for every surgeon, infectious disease specialist, and critical care physician.
The Structure Behind the Mechanism
Understanding how does metronidazole work requires appreciation of its chemical structure. The molecule consists of an imidazole ring with a nitro group (-NO₂) at position 5 and a hydroxyethyl side chain at position 1. This seemingly simple arrangement creates a compound with remarkable biological properties.
| Chemical Property | Value |
|---|---|
| IUPAC Name | 2-(2-methyl-5-nitro-1H-imidazol-1-yl)ethanol |
| Molecular Formula | C₆H₉N₃O₃ |
| Molecular Weight | 171.15 g/mol |
| CAS Number | 443-48-1 |
| Appearance | White to pale yellow crystalline powder |
| pKa | 2.6 |
| Water Solubility | 10 mg/mL at 20°C |
| Log P | -0.02 |
The nitro group at position 5 is the critical structural feature for antimicrobial activity. Without this group, the molecule loses all activity against anaerobic bacteria and protozoa. The reduction potential of this nitro group determines which organisms can activate the drug—specifically, organisms maintaining intracellular redox potentials below approximately -430 millivolts.
The hydroxyethyl side chain influences pharmacokinetic properties, including tissue distribution and metabolism. Its balanced lipophilicity (Log P of -0.02) explains metronidazole’s exceptional ability to cross biological membranes, including the blood-brain barrier, achieving cerebrospinal fluid concentrations nearly equal to serum levels.
Medicine’s Most Important Half-Life Lesson
Metronidazole’s 6-8 hour half-life determines every dosing decision. Master this concept across all medications: https://ssthem.org/half-life-of-medicines-complete-guide/
How Does Metronidazole Work: The Complete Mechanism of Action
The Prodrug Principle
How does metronidazole work as an antimicrobial? The answer begins with understanding that metronidazole is a prodrug—a medication that requires metabolic conversion within the target organism to become active. In its native form, metronidazole is relatively nontoxic to both human cells and aerobic bacteria. The transformation into a cytotoxic agent occurs only after the drug enters susceptible organisms and undergoes chemical reduction.
This prodrug mechanism explains metronidazole’s selective toxicity. Human cells maintain an oxygen-rich intracellular environment with a relatively high redox potential (approximately -250 to -300 mV). At this redox level, the nitro group of metronidazole remains stable and unreactive. Anaerobic bacteria, however, maintain intracellular redox potentials below -400 mV, providing the strongly reducing environment necessary to convert metronidazole into its active form.
Step-by-Step Molecular Mechanism
Step One: Passive Entry into Bacterial Cells
Metronidazole crosses bacterial membranes through passive diffusion, requiring no specific transporters or porins. Its small molecular size (171.15 g/mol) and balanced lipophilicity facilitate penetration through both outer and cytoplasmic membranes. This passive entry mechanism partly explains why resistance develops slowly—bacteria cannot simply mutate a transport protein to exclude the drug.
Step Two: Reduction of the Nitro Group
Once inside the bacterial cytoplasm, the nitro group undergoes single-electron reduction mediated by ferredoxin or flavodoxin, electron carrier proteins abundant in anaerobic organisms. The enzyme pyruvate:ferredoxin oxidoreductase (PFOR) plays a central role by generating reduced ferredoxin during pyruvate metabolism. This reduced ferredoxin then transfers electrons to metronidazole’s nitro group.
The reduction proceeds through several intermediates:
- Nitro group (-NO₂) → Nitroso radical anion
- Nitroso radical → Nitroso intermediate (-NO)
- Further reduction → Hydroxylamine derivative (-NHOH)
Step Three: Formation of Cytotoxic Compounds
The partially reduced intermediates, particularly the nitroso and hydroxylamine derivatives, are highly reactive and short-lived. These compounds attack multiple bacterial macromolecules simultaneously.
Step Four: DNA Damage
The reactive intermediates cause extensive DNA damage including single-strand breaks, double-strand breaks, and loss of helical structure. The damage overwhelms bacterial DNA repair mechanisms, triggering cell death. Unlike many antibiotics that merely inhibit growth, metronidazole is bactericidal—it kills susceptible organisms directly.
Step Five: Multi-Target Effects
Beyond DNA damage, metronidazole metabolites inhibit DNA polymerase, DNA repair enzymes, and various electron transport components. This multi-target mechanism makes resistance development through single mutations unlikely.
Why Oxygen Determines Activity
The answer to how does metronidazole work selectively against anaerobes lies in the competition between oxygen and the drug for electrons. In aerobic environments, molecular oxygen readily accepts electrons from reduced ferredoxin, preventing the reduction of metronidazole’s nitro group. Additionally, any nitro radical anions that form rapidly react with oxygen to regenerate the parent compound—a process called “futile cycling.” This oxygen-dependent detoxification protects aerobic cells while leaving anaerobic organisms vulnerable.
Pharmacodynamics: Concentration-Dependent Killing
Metronidazole exhibits concentration-dependent bacterial killing, meaning that higher drug concentrations produce more rapid and complete bacterial eradication. The key pharmacodynamic parameter is the peak concentration to minimum inhibitory concentration ratio (Cmax/MIC). This supports less frequent, higher-dose administration for serious infections, with the post-antibiotic effect lasting 1-3 hours against most susceptible anaerobes.
Pharmacokinetics: How Metronidazole Moves Through the Body
Understanding how does metronidazole work clinically requires knowledge of its pharmacokinetic behavior—how the body absorbs, distributes, metabolizes, and eliminates the drug.
Absorption
Oral metronidazole demonstrates exceptional bioavailability exceeding 90%, meaning that oral administration achieves serum concentrations nearly identical to intravenous infusion. Absorption occurs primarily in the small intestine through passive diffusion. Food may delay the time to peak concentration by 1-2 hours but does not significantly reduce total absorption. Peak plasma concentrations of 10-15 mcg/mL occur 1-3 hours after a standard 500 mg oral dose.
Distribution
Metronidazole distributes widely throughout body tissues and fluids, with an apparent volume of distribution of 0.6-1.0 L/kg. The drug crosses the blood-brain barrier efficiently even without meningeal inflammation, achieving cerebrospinal fluid concentrations of 43-100% of simultaneous serum levels. This exceptional CNS penetration makes metronidazole invaluable for brain abscesses and other intracranial anaerobic infections.
Metabolism and Elimination
Hepatic metabolism accounts for approximately 60-80% of metronidazole elimination, primarily through oxidation of the hydroxyethyl side chain by CYP3A4. The major hydroxy metabolite retains 30-65% of the parent compound’s antimicrobial activity. Renal excretion eliminates 60-80% of the administered dose as metabolites and approximately 20% as unchanged drug. The elimination half-life of 6-8 hours in adults with normal hepatic function supports dosing every 6-8 hours for serious infections.
| Parameter | Value |
|---|---|
| Bioavailability (oral) | >90% |
| Peak plasma time | 1-3 hours |
| Volume of distribution | 0.6-1.0 L/kg |
| Protein binding | <20% |
| Metabolism | Hepatic (CYP3A4) |
| Half-life (normal hepatic function) | 6-8 hours |
| Half-life (severe hepatic impairment) | 18-29 hours |
| Renal clearance | 60-80% of total elimination |
Bioavailability: Why Oral Metronidazole Equals IV
Metronidazole’s >90% bioavailability means oral therapy matches intravenous efficacy. Understand this critical concept: https://ssthem.org/bioavailability-in-pharmacology/
Spectrum of Activity: What Metronidazole Treats and What It Misses
How does metronidazole work against different organisms? The answer depends entirely on whether the organism maintains an anaerobic metabolism capable of reducing the drug’s nitro group.
Highly Susceptible Anaerobic Bacteria
Gram-Negative Anaerobes:
- Bacteroides fragilis group (the most clinically important anaerobic pathogen)
- Prevotella species (P. melaninogenica, P. intermedia, P. bivia)
- Porphyromonas species (P. gingivalis, P. asaccharolytica)
- Fusobacterium species (F. nucleatum, F. necrophorum)
- Veillonella species
Gram-Positive Anaerobes:
- Clostridium species (C. perfringens, C. septicum, C. novyi)
- Clostridioides difficile
- Peptostreptococcus and Peptococcus species
- Finegoldia magna
Protozoal Pathogens:
- Trichomonas vaginalis
- Entamoeba histolytica
- Giardia lamblia
- Balantidium coli
Inherently Resistant Organisms
All aerobic bacteria resist metronidazole because their intracellular redox potential remains too high for drug activation. This includes:
- Staphylococcus aureus (including MRSA)
- Streptococcus species
- Escherichia coli
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
Facultative anaerobes grown under aerobic conditions resist metronidazole for the same reason. This resistance explains why metronidazole must always be combined with aerobic coverage when treating mixed aerobic-anaerobic infections.
Resistance Mechanisms
Resistance to metronidazole occurs through several mechanisms:
- Decreased activity of pyruvate:ferredoxin oxidoreductase
- Overexpression of efflux pumps encoded by nim genes
- Production of nitroimidazole reductases that detoxify the drug
- Reduced drug penetration through outer membrane alterations
Current resistance rates remain low for most anaerobic pathogens (1-5% for B. fragilis in most regions), though higher rates have been reported from some centers in South Asia and the Middle East. H. pylori resistance ranges from 20-40% in many regions, compromising metronidazole-containing eradication regimens.
The Antibiotic That Revolutionized Medicine
Understanding metronidazole’s anaerobic mechanism reveals only half the antibiotic story. Learn amoxicillin’s clinical secrets: https://ssthem.org/life-changing-amoxicillin-secrets/
FDA-Approved and Evidence-Based Uses of Metronidazole
Understanding how does metronidazole work leads directly to its clinical applications. Each indication reflects the drug’s unique ability to target anaerobic bacteria and specific protozoa.
1. Trichomoniasis
Trichomonas vaginalis, an anaerobic protozoan, causes the most common non-viral sexually transmitted infection globally. Metronidazole remains first-line therapy, with a single 2-gram oral dose curing approximately 90-95% of infections. The 7-day regimen (500 mg twice daily) offers slightly higher cure rates and is preferred during pregnancy and for HIV-infected women.
2. Bacterial Vaginosis
Bacterial vaginosis involves overgrowth of anaerobic bacteria including Gardnerella vaginalis, Prevotella species, and Mobiluncus species. Metronidazole 500 mg orally twice daily for 7 days achieves cure rates of 70-80%. Topical vaginal gel formulations offer similar efficacy with fewer systemic side effects.
3. Amebiasis
Entamoeba histolytica causes intestinal amebiasis and amebic liver abscesses. Metronidazole 750 mg three times daily for 7-10 days effectively treats tissue-invasive disease. A luminal amebicide (paromomycin or iodoquinol) should follow to eliminate cysts from the intestinal lumen.
4. Giardiasis
Giardia lamblia infection responds to metronidazole 250 mg three times daily for 5-7 days. While tinidazole offers simplified single-dose therapy, metronidazole remains widely used due to its availability and low cost.
5. Clostridioides difficile Infection
C. difficile colitis represents one of the most important indications for oral metronidazole. The drug achieves high intraluminal concentrations in the colon. Current IDSA/SHEMA guidelines recommend metronidazole for non-severe initial episodes when vancomycin or fidaxomicin are unavailable, at 500 mg three times daily for 10 days.
6. Intra-abdominal Infections
Anaerobic bacteria, particularly Bacteroides fragilis, dominate complicated intra-abdominal infections. Metronidazole 500 mg IV every 6-8 hours, combined with an agent covering gram-negative aerobes, provides standard anaerobic coverage. The drug’s excellent peritoneal penetration ensures therapeutic concentrations at the infection site.
7. Brain Abscess
Metronidazole’s exceptional CNS penetration makes it essential for empiric brain abscess treatment. The combination of ceftriaxone, metronidazole, and vancomycin covers the most common pathogens: streptococci, anaerobes, and staphylococci.
8. Pelvic Inflammatory Disease
Anaerobic bacteria ascend in complicated PID, particularly when tubo-ovarian abscesses develop. CDC guidelines recommend metronidazole 500 mg twice daily as part of combination parenteral therapy for inpatient PID management.
9. Surgical Prophylaxis
Colorectal surgery carries high risk of anaerobic surgical site infections. Preoperative metronidazole 500 mg IV, combined with cefazolin, administered within 60 minutes before incision, significantly reduces postoperative infection rates.
10. Periodontal Infections
Anaerobic bacteria dominate periodontal disease. Metronidazole, alone or combined with amoxicillin, provides effective adjunctive therapy for aggressive periodontitis. Dental gel formulations allow localized treatment with minimal systemic exposure.
11. Rosacea (Topical)
Topical metronidazole reduces inflammatory lesions in rosacea through both antimicrobial and anti-inflammatory effects. The 0.75% and 1% formulations require 4-8 weeks for optimal response.
12. Helicobacter pylori Eradication
Metronidazole features in bismuth quadruple therapy for H. pylori eradication, particularly in regions with high clarithromycin resistance. However, metronidazole resistance compromises efficacy, and susceptibility testing guides optimal regimen selection.
13. Tetanus
Metronidazole 500 mg IV every 6-8 hours targets Clostridium tetani at the wound site, reducing vegetative bacterial forms. It does not neutralize preformed toxin, so antitoxin and supportive care remain essential.
14. Bacterial Septicemia
When anaerobic bacteremia is suspected or confirmed, metronidazole provides reliable coverage. Blood cultures positive for Bacteroides species should prompt metronidazole therapy pending susceptibility results.
15. Necrotizing Enterocolitis (Neonates)
Severe necrotizing enterocolitis involves anaerobic gut flora. Metronidazole is included in broad-spectrum regimens for critically ill neonates, though evidence remains limited.
Comprehensive Dosage Guidelines
Important Notice: These dosage recommendations represent general guidance based on current literature. Individual dosing decisions require qualified healthcare professional assessment considering the patient’s specific condition, organ function, and local guidelines.
Adult Dosing
| Indication | Regimen | Duration |
|---|---|---|
| Trichomoniasis | 2 g single dose OR 500 mg BID | Single dose or 7 days |
| Bacterial vaginosis | 500 mg BID | 7 days |
| Amebiasis | 750 mg TID | 7-10 days |
| Giardiasis | 250 mg TID | 5-7 days |
| Anaerobic infections | 500 mg IV/PO q6-8h | 7-14 days |
| C. difficile | 500 mg PO TID | 10 days |
| Surgical prophylaxis | 500 mg IV (single pre-op dose) | Single dose |
| H. pylori | 500 mg BID (with combination) | 10-14 days |
Pediatric Dosing
Pediatric dosing requires careful weight-based calculation:
| Indication | Pediatric Dose | Maximum |
|---|---|---|
| Amebiasis | 35-50 mg/kg/day divided q8h | 750 mg/dose |
| Giardiasis | 15 mg/kg/day divided q8h | 250 mg/dose |
| Anaerobic infections | 30 mg/kg/day divided q6h | 4 g/day |
Dosing in Special Populations
Hepatic Impairment: Severe liver disease (Child-Pugh Class C) requires 50% dose reduction and extended dosing intervals.
Renal Impairment: No routine dose adjustment required for renal impairment alone, though active metabolite accumulation occurs.
Hemodialysis: Administer scheduled dose after dialysis on treatment days, as hemodialysis efficiently removes metronidazole.
Pregnancy: The 7-day regimen at 500 mg twice daily is preferred over single-dose therapy during pregnancy.
Side Effects: What Patients Experience
Understanding how does metronidazole work helps explain its side effect profile. The drug’s distribution into saliva produces the characteristic metallic taste. Its CNS penetration accounts for neurologic symptoms at high doses or with prolonged therapy.
Common Side Effects (1-10%)
| Side Effect | Frequency | Management |
|---|---|---|
| Metallic taste | 10-15% | Reassurance; resolves after treatment |
| Nausea | 10-12% | Take with food |
| Headache | 5-10% | Standard analgesics |
| Dark urine | Common | Reassurance; harmless metabolite effect |
| Diarrhea | 5-10% | Monitor; report if severe or bloody |
Serious Side Effects (Rare)
- Peripheral neuropathy (prolonged therapy)
- Seizures (high doses)
- Aseptic meningitis
- Optic neuropathy
- Agranulocytosis (extremely rare)
Managing Antibiotic Side Effects Effectively
Side effect anticipation improves adherence dramatically. Learn co-amoxiclav management strategies: https://ssthem.org/co-amoxiclav-side-effects/
Drug Interactions: Clinical Significance
Critical Interactions
| Drug | Effect | Action |
|---|---|---|
| Warfarin | Increased INR | Monitor INR; reduce warfarin dose |
| Lithium | Lithium toxicity | Monitor lithium levels |
| Alcohol | Disulfiram-like reaction | Absolute abstinence during and 72h after therapy |
| Phenytoin | Reduced metronidazole efficacy | Monitor clinical response |
| Cyclosporine | Nephrotoxicity risk | Monitor renal function and cyclosporine levels |
The Alcohol Interaction Explained
How does metronidazole work to produce disulfiram-like reactions with alcohol? Metronidazole inhibits aldehyde dehydrogenase, the enzyme that converts acetaldehyde (the first alcohol metabolite) to harmless acetic acid. Acetaldehyde accumulation causes flushing, throbbing headache, nausea, vomiting, tachycardia, and hypotension. Patients must avoid all alcohol—including in mouthwashes, cough syrups, and food preparations—during therapy and for 72 hours after the last dose.
Pregnancy and Breastfeeding Safety
Current evidence from multiple large cohort studies demonstrates no increased risk of congenital malformations with metronidazole exposure during any trimester. The CDC and ACOG consider metronidazole acceptable during pregnancy when clinically indicated. For trichomoniasis and bacterial vaginosis during pregnancy, the 7-day oral regimen (500 mg twice daily) is preferred over single-dose therapy.
Breastfeeding considerations: Metronidazole transfers into breast milk achieving concentrations approaching maternal serum levels. Short-term therapy (7-10 days) is generally considered compatible with breastfeeding by most experts. The CDC recommends interrupting breastfeeding for 12-24 hours after single 2-gram doses. Topical and vaginal formulations result in minimal systemic absorption and are considered safe during lactation.
Discover Holistic Health and Beauty Insights
Complement your medical knowledge with wellness wisdom. ssthem.net shares expert health and beauty tips that healthcare professionals recommend to their patients.
Question. How does metronidazole work to kill bacteria?
Question. How does metronidazole work for BV?
Question. How does metronidazole work for trichomoniasis?
Question. How does metronidazole work for C. diff?
Question. How does metronidazole work for diarrhea?
Question. How does metronidazole work for rosacea?
Question. Why can’t I drink alcohol with metronidazole?
Question. Is metronidazole safe during pregnancy?
Question. How long does metronidazole stay in your system?
Question. What are metronidazole’s most common side effects?
Question. Does metronidazole treat UTIs?
Question. Can I take metronidazole while breastfeeding?
Question. How fast does metronidazole work?
Question. Does metronidazole treat yeast infections?
Question. What foods should I avoid with metronidazole?
Question. Can metronidazole cause dark urine?
Question. Is metronidazole a strong antibiotic?
Question. Does metronidazole treat sinus infections?
Question. What happens if I miss a metronidazole dose?
Question. Can metronidazole treat tooth infections?
Clinical Guidelines Summary
IDSA/SHEMA 2021 C. difficile Guidelines: Metronidazole 500 mg TID for 10 days is acceptable for non-severe initial episodes when first-line agents (vancomycin, fidaxomicin) are unavailable. IV metronidazole serves as adjunctive therapy for fulminant disease with ileus.
CDC 2021 STI Treatment Guidelines: Trichomoniasis: Metronidazole 500 mg BID for 7 days (women) or 2 g single dose (men). Bacterial vaginosis: Metronidazole 500 mg BID for 7 days or 0.75% gel intravaginally for 5 days.
ASHP/IDSA/SIS/SHEA Surgical Prophylaxis Guidelines: Colorectal surgery: Cefazolin 2 g IV plus metronidazole 500 mg IV within 60 minutes before incision. Re-dose at 8-hour intervals for prolonged procedures.
Key Takeaways
Understanding how does metronidazole work reveals a drug that is simultaneously simple in concept and sophisticated in execution. Its prodrug mechanism, requiring anaerobic activation, provides selective toxicity that has saved countless lives over nearly seven decades of clinical use. The drug’s excellent bioavailability, wide tissue distribution including CNS penetration, and generally favorable safety profile make it indispensable across multiple medical specialties.
Clinicians must remember that metronidazole treats anaerobic bacteria and specific protozoa—not aerobic organisms. This fundamental principle guides appropriate empiric therapy and prevents prescribing errors that could leave patients inadequately treated. When used correctly, with attention to dosing, drug interactions, and the critical alcohol contraindication, metronidazole remains one of medicine’s most valuable therapeutic tools.
References
1. Edwards DI. Nitroimidazole drugs—action and resistance mechanisms. J Antimicrob Chemother. 1993;31(1):9-20.
2. Löfmark S, Edlund C, Nord CE. Metronidazole is still the drug of choice for treatment of anaerobic infections. Clin Infect Dis. 2010;50(S1):S16-S23.
3. Freeman CD, Klutman NE, Lamp KC. Metronidazole: a therapeutic review and update. Drugs. 1997;54(5):679-708.
4. CDC. Sexually Transmitted Infections Treatment Guidelines. MMWR Recomm Rep. 2021;70(4):1-187.
5. Johnson S, et al. Clinical Practice Guideline by IDSA and SHEA: 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73(5):e1029-e1044.
6. Bratzler DW, et al. Clinical practice guidelines for antimicrobial prophylaxis in surgery. Am J Health Syst Pharm. 2013;70(3):195-283.
7. Zar FA, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea. Clin Infect Dis. 2007;45(3):302-307.
8. Kissinger P, et al. Single-dose versus 7-day-dose metronidazole for the treatment of trichomoniasis in women. Lancet Infect Dis. 2018;18(11):1251-1259.
9. Workowski KA, Bolan GA. Sexually transmitted diseases treatment guidelines, 2015. MMWR Recomm Rep. 2015;64(RR-03):1-137. (Updated 2021)
10. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 13th Edition. McGraw-Hill; 2018.
Disclaimer: This article is for educational purposes only and does not constitute medical advice. Treatment decisions must be made by qualified healthcare professionals based on individual patient assessment, current guidelines, and local resistance patterns. Always consult a licensed physician before starting, changing, or stopping any medication.
